Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03849118 · ClinicalTrials.gov registry record · Phase 3
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
A Phase 3 study, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT03849118 is a Phase 3 study that has completed, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 300 participants.
The verdict
NCT03849118, a Phase 3 study, has completed, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
Interventions
- DIAGNOSTIC_TEST 89Zr-girentuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2022-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03849118
The ClinicalTrials.gov registry entry for NCT03849118 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 89Zr-girentuximab is the first listed.
NCT03849118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03849118 about?
NCT03849118 is a clinical study titled "89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study". 89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
What is the current status of trial NCT03849118?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2019-08-15. Estimated completion is 2022-11-07.
What interventions are being tested in trial NCT03849118?
The interventions under investigation include: 89Zr-girentuximab (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03849118?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.